A Deuterated Ruxolitinib Derivative Among 14 Other Recent Notable Molecules
Other articles you may be interested in
August 2024 Molecule Roundup | >70 Molecules to Know
In this article, you'll find a curated selection of >70 molecules from August that piqued our interest, highlights of some of our favorites, and explanations of why they're worth watching.
SOS1 and SMARCA2 Degraders, RORγ and IRAK4 Inhibitors, and More: January 2024 Compound Collection
The team reviews hundreds of compounds from thousands of papers, press releases, and other sources each month to select candidates for Molecules of the Month. Here we have compiled a table of >70 additional molecules that were of interest in January 2024 along with highlights from some of our favorites, including molecules targeting SOS1, NLRP3, SMARCA2, and more.
Six Deals and Funding Rounds from July You May Have Missed
In case you missed anything while you were away on summer holiday, here’s a recap of six notable deals from July to get you up to speed.
September 2024 Molecule Roundup | >60 Molecules to Know
In this article, we present a curated selection of over 60 molecules from September that caught our attention, along with highlights of our top picks and insights into why they stand out.
Drug-Induced Liver Injury: A Medicinal Chemist’s Perspective
DILI is a leading cause of acute liver failure, accounting for half of these cases and often resulting in drug withdrawals. Understanding and managing DILI risk as a medicinal chemist involves exploring the intricate interplay among properties and structural features. In this article, we provide a medicinal chemist's perspective on the current understanding of DILI mechanisms, highlight cutting-edge assay developments for a holistic assessment, and discuss strategies for predicting DILI risks.
